Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Acta Chirurgica Latviensis

The Journal of Riga Stradins University; Latvian Association of Surgeons; Latvian Association of Paediatric Surgeons

2 Issues per year

Open Access
Online
ISSN
2199-5737
See all formats and pricing
More options …

Long – Term Intraocular Pressure Changes after Intravitreal Injections

Sintija Grava / Guna Laganovska
Published Online: 2018-09-25 | DOI: https://doi.org/10.1515/chilat-2017-0017

Abstract

Introduction. Direct drug delivery by intravitreal injection is an essential tool in the treatment of retinal diseases and the studies have demonstrated that patients undergoing treatment with intravitreal anti-VEGF agents may experience sustained and delayed elevation of intraocular pressure. According to literature, the incidence of sustained elevation of intraocular pressure varied from 3.45% - 11.6%. Aim of the Study.To research the changes of intraocular pressure after intravitreal injections in patients with a diagnosis of agerelated macular degeneration, diabetic maculopathy, and retinal vein occlusions. Material and Methods. A prospective study was done in Pauls Stradins Clinical University Hospital, Riga, Latvia from November 2015 - January 2016. In this study were interviewed and examined 31 patients who had had intravitreal injections. For data analysis, SPSS 23 was used. Results. From 31 patient there were 20 (65.5%) females and 11 (35.5%) males. They were divided into three groups depending on the diagnosis. There were 26 (83.9%) patients with age-related macular degeneration, 3 (9.7%) with diabetic retinopathy and 2 (6.5%) with retinal vein thrombosis. From 31 patient the IOP after intravitreal injections were increased in 21 (67.7%) patient - 13 (41.9%) in the right eye and 10 (32.2%) in the left eye. In both eyes the pressure was increased from 14 to 17 mmHg (14.08 to 17.08 mmHg in the right eye and 14.1 to 17.3 in the left eye). From 6 (19.3%) patients who had glaucoma before intravitreal injections, in 4 (66%) intraocular pressure had increased from 14.7 to 18.5 mmHg in the right eye and from 12.5 to 17 mmHg in the left eye. Conclusions. Patients with previously diagnosed glaucoma had a greater rise in intraocular pressure compared to patients with no glaucoma diagnosis. Further studies with a greater number of patients and identical intraocular pressure measuring method before and after injections are needed to better evaluate the effects of intravitreal injections on intraocular pressure.

Keywords: intravitreal injections; intraocular pressure; age-related macular degeneration

References

  • 1. Bakri SJ, Moshfeghi DM, Rundle A, et al // IOP in eyes treated with monthly ranibizumab: A post hoc analysis of data from the MARINA and ANCHOR trials. Paper presented at: Annual meeting of the American Academy of Ophthalmology; Chicago, IL; October 15, 2010Google Scholar

  • 2. Beato J.• Pedrosa A.C et al // Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age- Related Macular Degeneration. Ophthalmic Res 2016;56: 30-34Google Scholar

  • 3. Dedania VS, Bakri SJ // Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents. Retina 2015; 35: 841-858Google Scholar

  • 4. Good TJ Kimura AE, Mandava N, Kahook MY // Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114Google Scholar

  • 5. Kahook MY, Liu L, Ruzyck i P, et al // Highmolecular- weight aggregates in repackaged bevacizumab. Retina. 2010;30:887-892Google Scholar

  • 6. K Ghasemi Falavarjani and QD Nguyen // Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 2013; 27: 787-794Google Scholar

  • 7. Liu L, Ammar DA et al // Silicone oil microdroplets and protein aggregates in repacked bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52:1023-1034Google Scholar

  • 8. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents // Retina 2011; 31: 654-661Google Scholar

  • 9. Nurit Mathalone, Orna Geyer // Intraocular pressure elevations following intraocular injections of anti-VEGF agents. Retinal Physician. 2012;9: 26-32Google Scholar

  • 10. Rosenfeld PJ, Brown DM, Heier JS, et al // MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431Google Scholar

  • 11. Scott IU, Flynn Jr, HW. Reducing the risk of endophthalmitis following intravitreal injections // Retina 2007; 27: 10-12.Google Scholar

About the article

Published Online: 2018-09-25

Published in Print: 2017-12-20


Citation Information: Acta Chirurgica Latviensis, Volume 17, Issue 2, Pages 14–16, ISSN (Online) 2199-5737, DOI: https://doi.org/10.1515/chilat-2017-0017.

Export Citation

© 2018 Sintija Grava, published by Sciendo. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. BY-NC-ND 4.0

Comments (0)

Please log in or register to comment.
Log in